UNASSIGNED: The purpose of this study is to report our institutional experience using radiotherapy in the treatment of @entity1567 and @entity189 . Three @entity1 with @entity1567 and 3 @entity1 with @entity189 were treated with radiotherapy alone (2 @entity1 ) or surgery and postoperative radiotherapy (4 @entity1 ) at the University of Florida between 1973 and 2007. Follow-up ranged from 4.0 to 13.1  years with a median of 7.8  years. Radiotherapy complications were scored using the Common Terminology Criteria for Adverse Events, version 4.0. Local control was achieved in 4 of the 6 @entity1 . One @entity1 treated with @entity138 alone for an unresectable @entity1567 developed a local recurrence and @entity3 in both the cervical lymph nodes and lungs, but had excellent response to dual @entity817 / @entity8047 inhibition with @entity5458 and @entity5459 . Another @entity1 treated with surgery and postoperative radiotherapy for an @entity189 recurred locally without @entity3 , but was not salvaged. No significant treatment-related complications were observed. For @entity1 with local recurrence or inadequate margins after surgery, adjuvant radiotherapy provides the potential for disease control. In the setting of metastatic disease, targeted therapies may provide an additional opportunity for salvage.

Treatment of XXXX and @entity189 with radiotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8047 :: ('5609', 'Gene') :: ['MEK'] @entity5459 :: ('MESH:C560077', 'Chemical') :: ['trametinib'] @entity1567 :: ('MESH:D000564', 'Disease') :: ['ameloblastoma'] @entity138 :: ('MESH:C563738', 'Disease') :: ['RT'] @entity189 :: ('MESH:D002277', 'Disease') :: ['ameloblastic carcinoma'] @entity5458 :: ('MESH:C561627', 'Chemical') :: ['dabrafenib'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases'] @entity817 :: ('673', 'Gene') :: ['BRAF']
@entity1567 :: (MESH:D000564,Disease) :: ['ameloblastoma']
